Stockscreener 앱 받기
7.04
3.03%
-0.22
시간 외 거래:
7.39
0.35
+4.97%
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLC - Defense World
Wells Fargo & Company MN Has $76,000 Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Tower Research Capital LLC TRC - Defense World
Oppenheimer Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $56.00 - Defense World
B. Riley Expects Reduced Earnings for Corbus Pharmaceuticals - Defense World
HC Wainwright Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $40.00 - Defense World
Wedbush Expects Weaker Earnings for Corbus Pharmaceuticals - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Royal Bank of Canada Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? - Zacks Investment Research
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
CRBP: RBC Capital Lowers Price Target, Maintains Outperform Rati - GuruFocus
Oppenheimer Lowers Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Reduced by Analyst | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Adjusted by RBC Capital | CRBP Stock News - GuruFocus
CRBP: HC Wainwright & Co. Lowers Price Target for Corbus Pharmaceuticals | CRBP Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk - marketscreener.com
Corbus Pharmaceuticals (CRBP) Sees Price Target Reduction | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals: Q1 Earnings Snapshot - CTPost
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Advances Clinical Pipeline Amid Q1 Loss - TipRanks
Corbus Pharmaceuticals (CRBP) Advances Pipeline with Promising E - GuruFocus
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals (CRBP) Advances Pipeline with Promising Early Trial Data | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Corbus Pharmaceuticals Secures FDA Fast Track for Cancer Drug as 3 Clinical Programs Hit Key Milestones - Stock Titan
Trading (CRBP) With Integrated Risk Controls - news.stocktradersdaily.com
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday - Defense World
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
3 Unconventional Cannabis Stocks to Watch in 2025 - Zacks Investment Research
Geode Capital Management LLC Acquires 13,773 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $59.13 Average Price Target from Analysts - American Banking and Market News
Press Release Distribution & PR Platform - ACCESS Newswire
Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $59.13 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
(CRBP) Trading Report - news.stocktradersdaily.com
We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth - Yahoo Finance
Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? - Yahoo Finance
CRBP stock touches 52-week low at $4.64 amid sharp annual decline - Investing.com
CRBP stock touches 52-week low at $4.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Where are the Opportunities in (CRBP) - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
0.15%
자본화:
|
볼륨(24시간):